ILet B 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination of these two agents provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled on diet and exercise alone or on monotherapy. ILet B 2 Tablet PR is administered orally, with dosing individualized based on patient response and tolerability. It is essential to monitor blood glucose levels regularly to optimize therapy and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. This medication should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to any component.